Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg News

Shionogi Drops to 12-Year Low on Corporate Governance Questions

November 01, 2011

Nov. 1 (Bloomberg) -- Shionogi & Co., the Japanese maker of the Crestor cholesterol pill, plunged to a 12-year low in Tokyo trading after Credit Suisse AG said disruptions to the drugmaker’s U.S. operations raises questions about corporate governance.

The distruptions relate to Shionogi’s acquisition of Alpharetta, Georgia-based Sciele Pharma Inc., Credit Suisse health-care analysts Fumiyoshi Sakai and Toshiyuki Tateno said in an Oct. 31 report.

“Corporate governance issues arise after significant reduction in guidance due to a downturn in its U.S. business,” the analysts said. “The company says it has now dealt with problems with accounting and product returns in the U.S., but the disruption to U.S. operations triggered by the Sciele acquisition raises questions about Shionogi’s corporate governance.”

Shionogi slumped as much as 6.3 percent to 1,007 yen in Tokyo trading. The shares declined 5.8 percent to 1,013 yen at 10:27 a.m. local time, the lowest since Nov. 9, 1999.

To contact the reporter on this story: Kanoko Matsuyama in Tokyo at

To contact the editor responsible for this story: Jason Gale at

blog comments powered by Disqus